Slide 1: Corporate Overview
Corporate Over view For investors and analyst s March 2026
Slide 2: Safe Harbor Statement
S a fe H a r b o r S tate m e nt This presentation contains “forward-looking statements” within the meaning of the entering into collaboration agreements with third parties and Compugen may not be Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the successful in gener
Slide 3: Our Vision
Our Vision Transforming patient lives by developing first-in-class therapeutics based on Compugen’s AI/ML-powered computational target discovery platform UnigenTM From Code to Cure® 3
Slide 4: Focus on novel immuno-oncology antibodies
Fo c u s o n n ove l i m m u n o - o n c o l o g y a nt i b o d i e s D i s c o v e r e d b y C o m p u g e n ’s c o m p u t a t i o n a l d i s c o v e r y p l a t f o r m - U n i g e n T M Rich clinical pipeline with validating partnerships >$1bn in milestones PLUS royalties Fully owned clinical p
Slide 5: Immuno-oncology pipeline focus on novel antibodies
Immuno-oncology pipeline focus on novel antibodies Programs Sponsor/ Stage and Indication (mechanism of action) Partner MAIA-ovarian COM701 maintenance therapy (anti-PVRIG Adaptive platform trial: relapsed platinum sensitive antibody) ovarian cancer, sub-trial 1 randomized vs. placebo COM701 + COM90
Slide 6: Differentiated TIGIT strategy
Differentiated TIGIT strategy
Slide 7: Rilvegostomig broad development strategy as monotherapy and ADC-IO combinations
R i l ve go sto m i g b ro a d d e ve l o p m e nt st rate g y a s m o n o t h e ra p y a n d p a r t o f A D C - I O c o m b i n at i o n s Potential reflect >$5B PYR target* Study name Indication Rilvegostomig monotherapy or in combination Data anticipated by AstraZeneca Primary endpoint PHASE 1 P
Slide 8: COM902 potential best-in-class anti-TIGIT antibody
CO M 9 0 2 p o te nt i a l b e st - i n - c l a s s a nt i - T I G I T a nt i b o d y Va l u e r e i n f o r c e d b y s t r a t e g i c c o l l a b o r a t i o n w i t h Compugen entitled to up COM902 Rilvegostomig to $225m milestone potential best-in-class AZ est. >$5bn PYR1 payments & tiered anti
Slide 9: Not all anti-TIGIT antibodies are created equally
N o t a l l a nt i - T I G I T a nt i b o d i e s a re c re ate d e q u a l l y Antibody format matters from COM902 • Bispecific approach: differentiated coordinated inhibition of PD- 1/TIGIT induces greater ex vivo activity than its components1 Anti-PD-1 Fab Anti-TIGIT Fab -2.5 0.0 2.5 5.0 Patient
Slide 10: COM701 - potential first-in-class anti-PVRIG antibody
COM701 - potential first-in-class anti-PVRIG antibody
Slide 11: COM701 potential first-in-class Fc reduced anti-PVRIG antibody
CO M 7 0 1 p o te nt i a l 1 st i n c l a s s Fc re d u c e d a nt i - P V R I G a nt i b o d y COM701 Fc Reduced POTENTIAL FIRST-IN-CLASS Phase 1 data presented; proof-of-concept studies ongoing COM701 IgG4 reduced Fc effector function Avoids CD8 + T cell depletion and potential associated risks Bi
Slide 12: Strong biological rationale to target PVRIG in ovarian cancer
S t ro n g b i o l o g i c a l rat i o n a l e to ta rget P V R I G i n o va r i a n c a n c e r • High PVRIG pathway expression levels in ovarian cancer • PVRIG pathway differentially expressed on early differentiated stem like memory T cells and dendritic cells compared to other immune checkpoints
Slide 13: COM701 showed clinical benefit in platinum resistant ovarian cancer
CO M 7 0 1 s h o we d c l i n i c a l b e n ef i t i n p at i e nt s w i t h h a rd - to - t re at p l at i n u m re s i sta nt o va r i a n c a n c e r Ty p i c a l l y, n o t r e s p o n d i n g t o i m m u n o t h e r a p y 1 - 3 Safety and tolerability profile in Patient characteristics Encourag
Slide 14: Strong rationale to advance COM701 development to platinum sensitive ovarian cancer
S t ro n g c l i n i c a l a n d b i o l o g i c a l rat i o n a l e to a d va n c e CO M 7 0 1 d e ve l o p m e nt to p l at i n u m s e n s i t i ve o va r i a n c a n c e r High PVRIG pathway expression levels in ovarian cancer and PVRIG unique biology differentiated from other checkpoints suppor
Slide 15: MAIA-ovarian: adaptive trial with maintenance COM701 therapy
M A I A - o va r i a n : a d a p t i ve t r i a l w i t h m a i nte n a n c e CO M 7 0 1 t h e ra p y i n re l a p s e d p l at i n u m s e n s i t i ve o va r i a n c a n c e r Sub-trial 1 Key eligibility Endpoints Single agent activity of COM701 criteria versus placebo (standard of care) Primary:
Slide 16: Advancing COM701 to address unmet need in PSOC
A d va n c i n g CO M 7 0 1 to a d d re s s u n m et n e e d i n P S O C Building on data generated in PROC Platinum Sensitive Ovarian Cancer (PSOC) Platinum Resistant Ovarian Cancer (PROC) Platinum free ≥6-month before relapse Platinum free <6-month before relapse Immune system more compromised and
Slide 17: GS-0321 potential first-in-class anti-IL18BP antibody
G S - 0 3 2 1 ( p re v i o u s l y CO M 5 0 3 ) – p o te nt i a l f i rst - i n - c l a s s a nt i - I L 1 8 B P a nt i b o d y
Slide 18: Compugen identified potential dominant immunosuppression mechanism
G S - 0 3 2 1 : C o m p u ge n i d e nt i f i e d p o te nt i a l d o m i n a nt i m m u n o s u p p re s s i o n m e c h a n i s m a n d a nt i b o d y t h e ra p e u t i c Interleukin-18 binding protein, an endogenous inhibitor of interleukin -18 DAMPs Myeloid/ Inflammasome IL-18 immune stimulator
Slide 19: GS-0321 differentiated approach to harness cytokine biology
G S - 0 3 2 1 d i f fe re nt i ate d a p p ro a c h to h a r n e s s c y to k i n e b i o l o g y License agreement with Key Benefits up to $848M deal value Signed December 2023 Highlights potential of GS-0321 differentiated approach to harness cytokine biology to treat cancer $60 million upfront an
Slide 20: Advantages of differentiated approach
G S - 0 3 2 1 : a d va nta ge s o f a d i f fe re nt i ate d a p p ro a c h GS-0321 anti-IL-18 binding protein Recombinant cytokines Novel antibody approach Multiple challenges, no FDA approval in last 30 years Novelty Anti-IL-18BP releases endogenous IL-18 in the TME Systemic administration of a re
Slide 21: First-in-human global Phase 1 trial in advanced solid tumors
G S - 0 3 2 1 f i rst - i n - h u m a n g l o b a l P h a s e 1 t r i a l i n p at i e nt s w i t h a d va n c e d s o l i d t u m o rs Key eligibility criteria First in human dose Endpoints Advanced recurrent or escalation dose Primary: safety and identify metastatic solid tumor expansion trial rec
Slide 22: Differentiated by integrating computational capabilities with drug development
D i f fe re nt i ate d b y i nte g rat i n g p i o n e e r i n g c o m p u tat i o n a l c a p a b i l i t i e s w i t h i m m u n o - o n c o l o g y d r u g d e ve l o p m e nt
Slide 23: AI/ML-powered validated computational platform for target discovery
a f l ex i b l e - l o o p A I / M L - p o we re d va l i d ate d c o m p u tat i o n a l p l at fo r m fo r ta rget d i s c o ve r y & d e ve l o p m e nt 23
Slide 24: Experienced Team Leading Compugen
E x p e r i e n c e d Te a m L e a d i n g C o m p u ge n
Slide 25: Diverse experienced leadership team
D i ve rs e ex p e r i e n c e d l e a d e rs h i p te a m Management team Board Of Directors Eran Ophir, PhD Michelle Anat Cohen-Dayag, PhD David Silberman Mahler, MD Executive Chair of the Board President and Chief Executive Officer Chief Financial Officer Chief Medical Officer Eran Ophir, PhD Pre
Slide 26: Strategic advisors
S t rate g i c a d v i s o rs Industry veterans, renowned oncologists and immunologists Scientific Advisory Board Drew Pardoll, MD, PhD Antoni Ribas, MD, PhD Nils Lonberg, PhD Elliott Sigal, MD, PhD Chairman Former SVP, Oncology Discovery Biology Strategic Advisor Bristol Myers Squibb Former CSO, EV
Slide 27: Deep dive into COM701 data in platinum resistant ovarian cancer
D e e p d i ve i nto CO M 7 0 1 d ata i n p l at i n u m re s i sta nt ova r i a n c a n c e r
Slide 28: COM701 clinical benefit across multiple tumors
CO M 7 0 1 c l i n i c a l b e n ef i t a c ro s s m u l t i p l e t u m o rs t y p i c a l l y u n re s p o n s i ve to i m m u n o t h e ra p y TUMOR TREATMENT MED PRIOR LINES BEST RESPONSE DESCRIPTION REFERENCE IO BENCHMARK 6 1/6 ORR (16.6%) COM701 1 PR >18 months~* in immune desert TME ASCO 2021
Slide 29: Characterizing PROC responding patients across Phase 1
C h a ra c te r i z i n g P RO C re s p o n d i n g p at i e nt s a c ro s s P h a s e 1 Guided the design of ongoing MAIA-ovarian PSOC maintenance platform trial Patients without liver metastases - Patients derived clinical benefit irrespective of PD-L1 status more likely to derive clinical benefit
Slide 30: COM701 single agent activity: Partial response >18 months
CO M 7 0 1 s i n g l e a ge nt a c t i v i t y : Pa r t i a l re s p o n s e > 1 8 m o nt h s * PD-L1 neg ovarian cancer patient supported by immune activation Patient received 3 prior lines of anti cancer therapy PVRL2 PD-L1 Increase in IFNγ induction and immune activation in peripheral blood • Pre
Slide 31: COM701 monotherapy: partial response in PD-L1 negative ovarian cancer
CO M 7 0 1 m o n o t h e ra p y : p a r t i a l re s p o n s e i n p at i e nt w i t h P D - L 1 n e gat i ve o va r i a n o n go i n g t re at m e nt > 1 8 m o nt h s 63-year-old female with microsatellite stable platinum resistant primary peritoneal cancer Had 3 prior lines of SOC treatment PDL1 n
Slide 32: Consistent efficacy and safety with COM701 triplet combination
C o n s i ste nt ef f i c a c y & s a fet y w i t h CO M 7 0 1 t r i p l et c o m b i n at i o n In platinum resistant ovarian cancer patients who have exhausted all options The safety and tolerability profile generally Efficacy consistent with approved anti-PD-(L)1s Investigator assessed by RECIST
Slide 33: Consistent durable responses demonstrated across studies
C o n s i ste nt d u ra b l e re s p o n s e s d e m o n st rate d a c ro s s st u d i e s In platinum resistant ovarian cancer patients who have exhausted all options A. COM701 + nivolumab + BMS-9862071 20% ORR B. COM701 + pembrolizumab + COM9022 17% ORR 180 days 45% DCR 180 days 46% DCR 566 262 53
Slide 34: Consistent deep responses across studies
C o n s i ste nt d e e p re s p o n s e s a c ro s s st u d i e s In platinum resistant ovarian cancer patients who have exhausted all options COM701 + nivolumab + BMS-9862071 COM701 + pembrolizumab + COM9022 80 66 150 57 60 47 42 108 39 97.2 40 100 Best Percent Change from Baseline (%) Best Percent
Slide 35: Clinical vignette - COM701 plus pembrolizumab plus COM902
C l i n i c a l V i g n ette – CO M 7 0 1 + p e m b ro l i z u m a b + CO M 9 0 2 c o m p l ete re s p o n s e i n P RO C p at i e nt 4 p r i o r l i n e s o f t h e r a p y i n c l u d i n g c h e m o t h e r a p y, b e v a c i z u m a b m a i n t e n a n c e a n d a n investigational agent ( smac-
Slide 36: Clinical vignette - COM701 plus nivolumab partial response
C l i n i c a l V i g n ette – CO M 7 0 1 + n i vo l u m a b p a r t i a l re s p o n s e i n n i vo l u m a b ref ra c to r y P RO C p at i e nt Received 7 prior lines of therapy including progressed disease on nivolumab 53-year-old female with high grade serous Increased CD8+ T cell infiltration a
Slide 37: Clinical benefit and TME T cell clonal expansion
C l i n i c a l b e n ef i t a n d T M E T c e l l c l o n a l ex p a n s i o n i n d e p e n d e nt o f b a s e l i n e i n f l a m m ato r y stat u s Platinum Resistant Ovarian Cancer Patients TME T cell clonal expansion in patients who derived clinical benefit from Baseline inflammatory status CO
Slide 38: COM701 safety profile may provide differentiation in earlier settings
CO M 7 0 1 s a fet y p ro f i l e m ay p rov i d e c l i n i c a l l y re l e va nt d i f fe re nt i at i o n i n e a r l i e r c a n c e r s ett i n g s The safety and tolerability profile was generally consistent with approved anti-PD-(L)1s as monotherapy and in combination across tumors COM701 ±
Slide 39: COM902 - potential best-in-class anti-TIGIT antibody
C O M 9 0 2 - p o te n t i a l b e s t - i n - c l a s s a n t i - T I G I T a n t i b o d y
Slide 40: COM902 monotherapy showed disease control
CO M 9 0 2 m o n o t h e ra p y s h o we d a 5 0 % d i s e a s e c o nt ro l rate 1 mg/kg Chordoma 344† 0.01 mg/kg Adenoid-cystic CA trachea 302 † 0.01 mg/kg Rectal CA 291 1 mg/kg Ovarian CA 131 0.1 mg/kg Peritoneal CA 83† 1 mg/kg Appendiceal CA 83* 10 mg/kg Colon CA 81 3 mg/kg Esophageal CA 70 COM9
Slide 41: Compugen differentiated in TIGIT space by unique properties
C o m p u ge n d i f fe re nt i ate d i n T I G I T s p a c e b y u n i q u e p ro p e r t i e s o f Fc re d u c e d CO M 9 0 2 a n d c l i n i c a l st rate g y • One of only two clinical stage Fc- reduced anti-TIGIT monoclonal antibodies • Combination of TIGIT with PD-1 Anti- PD-1 blockade may be
Slide 42: COM902 well tolerated safety profile
CO M 9 0 2 – we l l to l e rate d s a fet y p ro f i l e 1 Favorable safety and well tolerated COM902 naturally Fc reduced as monotherapy and in combination antibody (IgG4 backbone) chosen with COM902 ± COM701± pembrolizumab efficacy and safety in mind • Most commonly reported AEs were grade 1/2 Avo
Slide 43: COM902 prevents depletion of major TIGIT+ lymphocytes
CO M 9 0 2 p re ve nt s d e p l et i o n o f m a j o r T I G I T + ex p re s s i n g l y m p h o c y te s - N K , C D 4 a n d C D 8 T c e l l s Supporting rationale for selecting a high affinity anti -TIGIT antibody with an IgG4 backbone and low Fc effector function - COM902 CD4+ Naive CD8+ Naive CD
Slide 44: Deep dive into GS-0321 data
D e e p d i ve i nto G S - 0 3 2 1 d ata
Slide 45: GS-0321 fully human high affinity anti-IL-18BP antibody restores activity
G S - 0 3 2 1 , f u l l y h u m a n , h i g h a f f i n i t y a nt i - I L - 1 8 B P a nt i b o d y re sto re s h u m a n T I L a n d N K c e l l a c t i v i t y i n h u m a n a s s ay s GS-0321 restored GS-0321 restored GS-0321 enhanced T cell activation in NK cell activity TILs activity human diss
Slide 46: Anti-mouse IL-18BP antibody demonstrates monotherapy activity
A nt i - m o u s e I L - 1 8 B P a nt i b o d y d e m o n st rate s m o n o t h e ra p y a c t i v i t y a c ro s s m u r i n e sy n ge n e i c t u m o r m o d e l s aIL-18BP Ab inhibits tumor aIL-18BP Ab inhibits tumor aIL-18BP Ab inhibits tumor growth in E0771 orthotopic growth in MC38ova mouse gr
Slide 47: Anti-IL-18BP Ab expected to have a better therapeutic window
A nt i - I L 1 8 B P A b i s ex p e c te d to h ave a b ette r t h e ra p e u t i c w i n d o w t h a n re c o m b i n a nt c y to k i n e s Administration of anti-mouse IL-18BP Ab to mice did not affect serum cytokines in contrast to engineered mouse IL-18* IFNg TNFa MCP1 IL6 200 300 400 5000 Isoty
Slide 48: Appendix
Appendix
Slide 49: COM701 and COM902 distinguishing properties
CO M 7 0 1 a n d CO M 9 0 2 d i st i n g u i s h i n g p ro p e r t i e s Antibody characteristics • Humanized IgG4 antibody • High affinity (2 pM KD by KinExA) • Blocks PVRIG/PVRL2 binding interaction • Enhances T and NK cell activation alone and in combination with TIGIT and PD1 blockade • Favorab
Slide 50: PVRIG and TIGIT - complementary but distinct pathways
P V R I G a n d T I G I T – c o m p l e m e nta r y b u t d i st i n c t p at hway s PVRIG preferentially binds PVRL2 TIGIT preferentially binds PVR Differentially expressed in Differentially expressed on Differentially expressed in the tumor types immune cell types tumor microenvironment PVRL2 expr